IDH2
Kazia Therapeutics Joins Australian Umbrella Trial Studying Paxalisib in IDH-Mutant Glioma
The trial will evaluate paxalisib, Kazia's PI3K/AKT/mTOR inhibitor, and other targeted therapies in patients with grade 2 or 3 IDH-mutant gliomas.
Servier Eyes Approval for Vorasidenib After Positive Phase III Results in IDH1/2-Mutant Glioma
Premium
Vorasidenib increased progression-free survival and time to next treatment versus placebo in results from the INDIGO trial, presented at ASCO this week.
AstraZeneca's Lynparza Fails Phase II, Single-Arm Study in IDH-Mutant High-Grade Glioma
The trial did not meet its prespecified six-month progression-free survival rate, with only 11 of 35 patients reaching six months without progression.
Hutchison China MediTech Launches International Studies of IDH Inhibitor
The trials will enroll patients with solid and blood cancers in the US and Europe and study the activity of its small molecular inhibitor of IDH1/2 mutations.
Agios Sells Oncology Business to Servier for $1.8B Upfront
A range of drugs from Agios' cancer pipeline will be transferred to Servier, including two commercial drugs Tibsovo and Idhifa.
Apr 13, 2020
Mar 12, 2019